WO2019066161A1 - 세포질 이식을 이용한 복제배아의 재프로그래밍 효율 향상 방법 - Google Patents
세포질 이식을 이용한 복제배아의 재프로그래밍 효율 향상 방법 Download PDFInfo
- Publication number
- WO2019066161A1 WO2019066161A1 PCT/KR2018/001691 KR2018001691W WO2019066161A1 WO 2019066161 A1 WO2019066161 A1 WO 2019066161A1 KR 2018001691 W KR2018001691 W KR 2018001691W WO 2019066161 A1 WO2019066161 A1 WO 2019066161A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytoplasm
- oocyte
- oocytes
- somatic cells
- cloned
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 230000008672 reprogramming Effects 0.000 title claims abstract description 32
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 7
- 230000001086 cytosolic effect Effects 0.000 title abstract description 6
- 238000002054 transplantation Methods 0.000 title abstract description 5
- 210000002257 embryonic structure Anatomy 0.000 title description 37
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 65
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 28
- 241000124008 Mammalia Species 0.000 claims abstract description 21
- 230000001965 increasing effect Effects 0.000 claims abstract description 15
- 210000000287 oocyte Anatomy 0.000 claims description 95
- 210000000805 cytoplasm Anatomy 0.000 claims description 53
- 238000000338 in vitro Methods 0.000 claims description 14
- 230000010076 replication Effects 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 210000002969 egg yolk Anatomy 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- 241001465754 Metazoa Species 0.000 abstract description 9
- 238000010367 cloning Methods 0.000 abstract description 9
- 230000009261 transgenic effect Effects 0.000 abstract description 3
- 238000010362 genome editing Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 48
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 30
- 210000002459 blastocyst Anatomy 0.000 description 28
- 210000004940 nucleus Anatomy 0.000 description 16
- 241000283690 Bos taurus Species 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000002438 mitochondrial effect Effects 0.000 description 9
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 9
- 238000011529 RT qPCR Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000007159 enucleation Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 7
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 7
- 108010024985 DNA methyltransferase 3B Proteins 0.000 description 7
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 6
- 238000010804 cDNA synthesis Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
- 230000001850 reproductive effect Effects 0.000 description 6
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000001973 epigenetic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000001771 cumulus cell Anatomy 0.000 description 3
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 3
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 210000004508 polar body Anatomy 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012349 terminal deoxynucleotidyl transferase dUTP nick-end labeling Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000010311 mammalian development Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010449 nuclear transplantation Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- 241000945470 Arcturus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 101150065780 DNMT gene Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 241000251188 Holocephali Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000029803 blastocyst development Effects 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- IFTVAQUNDKGWDD-UHFFFAOYSA-M mitoTracker Green FM Chemical compound [Cl-].O1C2=CC=CC=C2N(C)C1=CC=CC(=[N+](C1=CC(Cl)=C(Cl)C=C11)C=2C=CC(CCl)=CC=2)N1C1=CC=C(CCl)C=C1 IFTVAQUNDKGWDD-UHFFFAOYSA-M 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000010373 organism cloning Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0273—Cloned vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
Definitions
- the present invention relates to a method for increasing somatic cell replication efficiency in a mammal, and more particularly, to a method for providing a high quality embryo by improving the reprogramming efficiency of a cloned embryo using a cytoplasmic transplantation technique.
- embryonic aggregation can be a good means of improving both the development rate of blastocysts and the quality of cloned embryos [Tang P-c, West JD. The effects of embryo stage and cell number on the composition of mouse aggregation chimaeras. Zygote. 2000; 8 (03): 235-43; Misica-Turner PM, Oback FC, Eichenlaub M, Wells DN, Oback B. Aggregating embryonic but not somatic nuclear transfer embryos increases cloning efficiency in cattle. Biol Reprod. 2007; 76 (2): 268-78).
- the present inventors investigated a method for increasing somatic cell replication efficiency in mammals, and in order to replicate somatic cells, the cytoplasm removed with nucleus and polar body was removed from the somatic cells of other oocytes, so that the reprogramming efficiency of somatic cells became very high, And the present invention has been completed.
- an object of the present invention is to provide a method for enhancing the reprogramming efficiency of a cloned embryo by injecting a cytoplasm together with somatic cells to be replicated in an enucleated oocyte.
- the present invention provides a method for improving the reprogramming efficiency of a cloned embryo, which comprises injecting somatic cells and cytoplasm to be replicated in enucleated oocytes in which the cytoplasm is lost.
- the inventors of the present invention found that transplantation of cytoplasmic transplants into enucleated oocytes was performed by using terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL), quantitative reverse transcription PCR and immunocytochemistry techniques, The effect of embryo development on embryo development and quality of small embryos was confirmed.
- TUNEL terminal deoxynucleotidyl transferase dUTP nick-end labeling
- immunocytochemistry techniques The effect of embryo development on embryo development and quality of small embryos was confirmed.
- the present inventors have developed a novel technology called cytoplasm injection cloning technology (CICT). This technique is a technique for transplanting the cytoplasm of another oocyte into the oocyte that has lost the cytoplasm during the enucleation, thereby regenerating the lost cytoplasm of the enucleated oocyte.
- CICT cytoplasm injection cloning technology
- the method of improving the reprogramming efficiency of the cloned embryo of the present invention may include injecting the cytoplasm of somatic cells and other oocytes to be cloned into the enucleated oocytes in which the cytoplasm is lost.
- the amount of cytoplasm of the injected other oocyte is approximately equal to the amount of cytoplasm lost in the enucleated oocyte. In other words, it can be injected with the original amount of cytoplasm present in the recipient oocyte.
- the amount of cytoplasm lost in the enucleated oocyte may be about 10-50% by volume of the total cytoplasm, but is not limited thereto.
- the method of enhancing the reprogramming efficiency of the cloned embryo comprises: incubating the cytoplasm of the somatic cells and other oocytes which are to be replicated in the enucleated oocyte with about 20 to 30% 30% by volume of the solution.
- the enucleated oocyte that has lost the cytoplasm used in the method for improving the reprogramming efficiency of the cloned embryo is prepared by inhaling the enucleated oocyte and the surrounding cytoplasm to enucleation .
- the step of injecting somatic cells and cytoplasm to be replicated comprises the steps of injecting a single round donor into the perivitelline space of the enucleated oocyte using a manipulation pipette somatic cells) and the cytoplasm of the donor oocyte.
- the method for enhancing the reprogramming efficiency of the cloned embryo may further include fusing the somatic cells and cytoplasm-impregnated oocytes through an SV mediated method.
- a method for improving the reprogramming efficiency of the cloned embryo comprises the steps of: (a) extracting somatic cells to be cloned from an individual having somatic cells to be cloned; (b) preparing enucleated oocytes with 20 to 30% by volume of the cytoplasm and nuclei from in vitro maturated oocytes; (c) extracting 20 to 30% by volume cytoplasm from the donor oocyte; (d) injecting cytoplasm extracted from donor oocytes with somatic cells extracted from the somatic cells to be replicated into the enucleated oocytes of step (b); And (e) fusing the somatic cells and cytoplasm-impregnated oocytes.
- the cloned embryo may be a cloned embryo of a mammal other than a human.
- the mammals other than humans may include pigs, cows, sheep, mice, dogs and the like, preferably, but not limited to, bees.
- the proportion of embryos in which dividing is performed and the blastocysts are formed is compared with that of the somatic cell nuclear transfer (SCNT) group [the donor somatic cells in the perivitelline space of the enucleated oocyte (61.5 ⁇ 1.3% vs. CICT group) of the present invention (group injected with cytoplasm of donor oocytes together with somatic cells into enucleated oocyte) 39.7 ⁇ 2.1% and 28.9 ⁇ 0.8% vs. 20.2 ⁇ 1.3%) (P ⁇ 0.05).
- SCNT somatic cell nuclear transfer
- CICT showed increased mitochondrial activity, and mRNA levels of DNA methyl transferase 1 and DNA methyl transferase 3a were much lower (P ⁇ 0.05) in the CICT group than in the SCNT group. DNA methyl transferase 3b mRNA levels were lower in the CICT group than in the SCNT group, but there was no significant difference (P> 0.05).
- the invention provides a method of increasing somatic cell replication efficiency in a mammal using a method of enhancing the reprogramming efficiency of said cloned embryo.
- a method of increasing the somatic cell replication efficiency of a mammal comprising: (a) extracting somatic cells to be replicated from a mammal; (b) preparing enucleated oocytes with 20 to 30% by volume of the cytoplasm and nuclei from in vitro maturated oocytes; (c) extracting 20 to 30% by volume cytoplasm from the donor oocyte; (d) injecting somatic cells extracted from the mammal and a cytoplasm extracted from a donor oocyte into the enucleated oocyte of step (b); (e) fusing the somatic cells and cytoplasm-impregnated oocytes; And (f) culturing the fused oocyte.
- the step (f) comprises culturing the fused oocyte in ionomycin for 1 to 10 minutes, treating DMAP (6-dimethylaminopurine) for 3 to 5 hours And activating.
- the mammal may be a mammal other than a human, and the mammal other than the human may include pigs, cows, sheep, mice, dogs and the like, But is not limited thereto.
- the present invention provides a cloned somatic cell animal produced by the above method.
- a desired gene can be inserted or deleted to be efficiently used for producing transgenic cloned animals. That is, it can be effectively used for the production of disease model animals and transgenic clones producing the physiologically active substances, and is also capable of restoring by replication of somatic cells of endangered species.
- FIG. 1 is a diagram schematically showing a method for increasing somatic cell replication efficiency of the present invention.
- Figure 2 shows the results of TUNEL analysis of 8 day blastocysts in IVF, SCNT and CICT groups.
- FIG. 3 shows the result of confirming the fluorescence intensity of mitochondria staining in the blastocyst of 8 days.
- FIG. 4 shows the results of confirming the relative mRNA expression level of the DNMT gene in the blastocyst determined by RT-qPCR.
- the present invention provides a method for producing a somatic cell clone of a mammal other than a human, comprising injecting 20 to 30% by volume of a cytoplasm of somatic cells and other oocytes having a characteristic of replicating in an enucleated oocyte at 20 to 30% And to a method for increasing the efficiency.
- step (b) 20 to 30% by volume of the cytoplasm may be extracted from the oocytes other than the oocytes used in step (a), and then injected together with the somatic cells.
- the activation of the oocyte fused in step (b) can be performed by incubating the cells in ionomycin for 1 to 10 minutes and treating DMAP (6-dimethylaminopurine) for 3 to 5 hours in fused oocytes .
- Nuclear transplantation' is a genetic engineering technique that allows an enucleated oocyte to artificially bind other cells or nuclei to have the same traits.
- Nuclear transfer embryos' refers to oocytes into which nuclear donor cells are introduced or fused.
- 'Cloning' is a genetic manipulation technique for creating a new individual having the same gene set as that of an individual.
- the present invention provides a gene manipulation technique in which a cell, an embryo cell, a fetal cell, and / or an adult cell is substantially the same nucleus DNA sequence.
- Nuclear donor cells refers to nuclei of cells or cells that deliver nuclei to recipient oocytes, which are nuclear receptors.
- recipient oocyte refers to an oocyte whose original nucleus has been removed through the enucleation process and the nucleus is transferred from the nuclear donor cell.
- " oocyte " preferably refers to a mature oocyte that has reached the middle stage of the second meiosis.
- 'enucleated oocyte' refers to the removal of the oocyte nucleus.
- lipid membrane can be a plasma membrane or a nuclear membrane of a cell. Fusion can occur by applying electrical stimulation when the nuclear donor cell and the recipient oocyte are adjacent to each other or when the nuclear donor cell is located in the perivitelline space of the recipient oocyte.
- Nuclear reprogramming' is a process in which nuclei of the donor cell line are incubated for a certain period of time after fusing the recipient oocyte and the donor cell during the nuclear transfer process, thereby inducing the normal development of the nuclear oocyte (cloned embryo) Process.
- 'Activation' refers to stimulation of cells to divide before, during, and after nuclear transfer.
- the present invention refers to stimulation in advance of the nuclear transfer step.
- Mammal means a mammal other than a human, and most preferably a pig, a cow, a sheep, a mouse, a dog, but is not limited thereto.
- somatic cell cloned animals In order to produce somatic cell cloned animals, it is necessary to remove the nucleus of the oocyte and inject somatic cells to be cloned and induce reprogramming by fusing to induce de-differentiation into 1-cell stage.
- the reprogramming of injected somatic cells is insufficient due to insufficient cytoplasm of 20 to 30% by volume removed in the enucleation, resulting in a very low production efficiency of cloned animals.
- the present invention uses a method of increasing the efficiency of reprogramming somatic cells by re-injecting 20 to 30% by volume of another enucleated cytoplasm.
- the embryo fusion rate was significantly higher than that of the SCNT group (see Table 2), and the quality of the blastocyst was also excellent (see Table 3).
- DNA methyl transferase 1 (DNMT1), DNA methyl transferase 3a (DNMT3a), the level of expression of the gene in the analysis of RT-qPCR to quantify the mRNA expression level of the DNA methyl transferase 3b (DNMT3b) is Housekeeping gene was normalized to the level of (housekeeping gene), GAPDH, mRNA expression levels of the gene was confirmed to significantly lower than SCNT group from the CICT group prepared by the method of the present invention (see Fig. 4).
- the cloned embryos produced using the method of the present invention were similar to those of the in vitro fertilized embryos and were significantly higher than those of the embryo-derived somatic cells.
- the donor somatic cells were derived from the skin tissue of Hanwoo livestock. Briefly, skin tissue was washed three times with Dulbecco's phosphate buffered saline (D-PBS, Invitrogen, Carlsbad, Calif., USA) and chopped to 1 mm 2 with 0.25% (v / v) Trypsin- EDTA solution (Gibco BRL , Life Technologies, Grand Island, NY, USA) at 37 < 0 > C for 1 hour.
- D-PBS Dulbecco's phosphate buffered saline
- v / v Trypsin- EDTA solution
- the cells were then incubated with 15% (v / v) fetal bovine serum (FBS, Gibco), 1% (v / v) L- glutamine, 1% (Becton Dickinson, Franklin Lakes, NJ, USA) in a donor cell culture medium supplemented with penicillin-streptomycin (Dulbecco's modified Eagles medium (DMEM, Gibco), centrifuged at 1,000 rpm for 2 minutes, USA). Divided cells were continuously cultured for 10-14 days in humidified air containing 5% CO 2 at 37 ° C in donor cell culture medium.
- FBS fetal bovine serum
- DMEM Dulbecco's modified Eagles medium
- passage # 3 The cells of passage # 3 were frozen in DMEM supplemented with 10% (v / v) FBS and 10% (v / v) dimethyl sulfoxide and stored in liquid nitrogen. Cells were thawed and cultured until passage # 4-8 and used for cloning.
- COCs Cumulus-oocyte complexes
- COCs with three or more layers of homogeneously granulated cytoplasm and compressed cumulus cells were selected, and TL-HEPES [114 mM sodium chloride, 3.2 mM potassium chloride, 2 mM sodium bicarbonate, 0.34 mM sodium biphosphate, The cells were washed with 10 mM sodium lactate, 0.5 mM magnesium chloride, 2 mM calcium chloride, 10 mM HEPES, 1 L / mL phenol red, and 1% (v / v) P / ) supplemented with 10% (v / v) FBS, 1 ⁇ g / mL estradiol-17 ⁇ , 10 ⁇ g / mL follicle-stimulating hormone, 0.6 mM cysteine, and 0.2 mM Na-pyruvate) and 600 ⁇ L IVM medium (Thermo Fisher Scientific, Waltham, MA, USA) and incubated for 22-24 hours in humidified air containing 5% CO 2 at 3
- the semen was thawed for 1 minute in a 37 ° C water bath.
- the sperm was washed and centrifuged at 1,800 x rpm for 5 minutes at room temperature and pelleted with D-PBS.
- the pellet was resuspended in vitro fertilization (IVF) medium [6 mg / mL bovine serum albumin (BSA) containing 20 / / mL heparin and cultured in a humidified environment containing 5% CO 2 at 38.5 ⁇ for 15 minutes ), 22 [mu] g / mL sodium pyruvate, 100 IU / mL penicillin and 0.1 mg / mL streptomycin).
- IVF vitro fertilization
- sperm suspension was diluted in IVF medium (final density 1-2 x 10 6 sperm / mL).
- Mature COCs were transferred to a 4-well dish containing sperm in 600 ⁇ L of IVF medium and cultured for 18-20 hours in a humidified environment containing 5% CO 2 at 38.5 ° C.
- erythrocytes were removed from COCs by repeated pipetting to 0.1% (v / v) bovine testis hyaluronidase produced in TL-HEPES. Dehydrated oocytes with a first polar body were selected for enucleation.
- enucleation was achieved by inhaling the first polar body and a small amount of peripheral cytoplasm in a small droplet of TCM-199 medium supplemented with 7.5 / / mL cytochalasin B (CB) and 0.3% BSA . Approximately 30% by volume of total enucleated oocytes were used as a source of cytoplasm. The remaining oocytes were used as recipient oocytes. The nuclear donor somatic cells were immersed in a solution of Sendai virus (SV, Cosmo Bio, Tokyo, Japan) for 1 minute.
- Sendai virus SV, Cosmo Bio, Tokyo, Japan
- a single round donor somatic cell ( ⁇ 20 ⁇ m) was injected (SCNT group) into the perivitelline space of each enucleated oocyte using an operation pipette (SCNT group), or a donor oocyte (CICT group) to recover the cytoplasm of the recipient oocyte ( Figure 1).
- the reconstructed oocyte was fused via SV mediated method (Song YH, Pinkernell K, Alt E. Stem cell-induced cardiac regeneration: Fusion / mitochondrial exchange and / or transdifferentiation Cell Cycle 2011; 10 (14): 2281-6) And then cultured in modified SOF-BE1 (synthetic oviduct fluid-bovine embryo 1) supplemented with 5 ⁇ g / mL CB for 2 hours. Successfully reconstructed oocytes were incubated for 5 min in 5 ⁇ M ionomycin and activated in 2 mM 6-dimethylaminopurine for 4 h in a humidified environment containing 5% CO 2 at 38.5 ° C.
- SOF-BE1 synthetic oviduct fluid-bovine embryo 1
- TUNEL terminal deoxynucleotidyl transferase dUTP nick-end labeling
- the immobilized embryos were washed with PVP-PBS (0.3% (w / v) polyvinylpyrrolidine) and incubated for 30 min at room temperature with permeabilized solution [0.5% (v / v) Triton X- 100 and 0.1% (w / v) sodium citrate].
- the embryos were washed twice with PVP - PBS and incubated with fluorescein - conjugated deoxyuridine triphosphate and terminal deoxynucleotide transferase in the dark for 1 hour.
- the embryos stained with TUNEL were washed with PVP-PBS and then incubated for 10 minutes in PVP-PBS containing 10 ⁇ g / mL Hoechst 33342, washed twice with PVP-PBS to remove excess Hoechst 33342 I put it on a glass slide.
- TUNEL - positive cells appeared bright red and showed apoptosis.
- TUNEL analysis was performed three times and 15 blastocysts per group were analyzed.
- Mitochondrial activity was assayed using a commercial kit (MitoTracker Green FM; Invitrogen) according to the manufacturer's instructions.
- the fixed 8-day blastocysts were washed three times with D-PBS and incubated with MitoTracker ® Green FM at 125 nm for 30 minutes at 37 ° C.
- the blastocysts were then rinsed twice with D-PBS and labeled with Hoechst 33342 for 10 min at room temperature in the dark. After staining, the blastocysts were placed on glass slides and examined under a confocal laser scanning Olympus Fluoview FV1000 microscope. The excitation wavelength was 594 nm and the emission was read at 608 nm.
- Mitochondrial fluorescence was quantified by subtracting the background density from each image using the ImageJ (National Institutes of Health, Bethesda, MD, USA, https://imagej.nih.gov/ij) and then standardizing. Twenty blastocytes per group were examined and the experiment was repeated three times.
- RNA concentration and purity were measured using a NANO DROP 2000c instrument (Thermo Fisher Scientific, Wilmington, DE, USA). RNA samples were stored at -80 ° C prior to use. The mRNA was reverse transcribed with the first complementary DNA (cDNA) according to the manufacturer's instructions using the iScript TM cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). Finally, cDNA was stored at -80 ° C until used for RT-qPCR analysis.
- cDNA first complementary DNA
- RT-qPCR assays were performed in a reaction volume of 10 ⁇ L containing 0.2 mM each of the small specific primers, 1 x iQ SYBR Green Supermix kit (iQ SYBR Green Supermix kit, Bio-Rad Laboratories, Inc.) and 3 ⁇ L of diluted cDNA was performed using a CFX98 real-time system (Bio 1 x iQ SYBR Green Supermix (iQ SYBR Green Supermix kit, Bio-Rad Laboratories, Inc.).
- PCR involves a 44 cycle denaturation step (95 ° C for 3 minutes) at 95 ° C for 15 seconds, 57 ° C for 20 seconds and 72 ° C for 30 seconds and a final extension step at 72 ° C for 5 minutes.
- Amplification was carried out using progressive denaturation and the fluorescence was continuously measured while increasing the temperature from 65 ° C to 95 ° C at a rate of 0.2 ° C per second. Quantitative analysis was performed using the ⁇ C (t) method. For all profiled genes, the internal coefficient of variation was calculated using an equation of standard deviation / mean value ⁇ 100.
- DNMT1 F AGGGAGACGTGGAGATGCTGR: CATGGAGCGCTTGAAGGAG AY244709
- DNMT3a F AGACATGTGGGTTGAACCCGR: GGCTCCCACAAGAGATGCAG AY271298
- DNMT3b F CAGGATGGGAAGGAGTTTGGAR: CACCAAACCACTGGACCCAC AY244710 151
- GAPDH F CCCAGAATATCATCCCTGCTR: CTGCTTCACCACCTTCTTGA NM_001034034 185
- the present inventors examined the effects of cytoplasmic migration on the cutting and embryo developmental performance at the 8th day after transplantation of the transformed embryo transferred to the second day and compared these ratios with the ratio of in vitro fertilized embryos.
- the fusion rate was significantly higher in the CICT group injected with about 30% by volume of the cytoplasm of the other oocytes by the method of the present invention than the SCNT group using the conventional method (82.0 ⁇ 0.3% vs. 68.3 ⁇ 1.5%; see Table 2).
- the number of divisions was significantly higher than in the SCNT group (61.5 ⁇ 1.3% vs. 39.7 ⁇ 2.1%) and lower than that of the IVF group (75.4 ⁇ 1.3% 2).
- the percentage of embryos developed with embryo blastocysts was significantly higher in the CICT group than in the SCNT group (28.9 ⁇ 0.8% vs. 20.2 ⁇ 1.3%), but there was no significant difference between the CICT and IVF groups (see Table 2).
- the total number of cells per blastocyst was significantly higher in the CICT group than in the SCNT group (176.2 ⁇ 6.5 vs. 119.3 ⁇ 7.7) (P ⁇ 0.05) and similar to the IVF group (184.0 ⁇ 8.7) And Fig. 2).
- the number of apoptotic cells in the CICT group per blastocyst was lower than in the SCNT group (3.5 ⁇ 1.1 vs. 4.1 ⁇ 0.8).
- these differences were not significant (see Table 3).
- the present inventors investigated the effect of cytoplasmic migration on mitochondrial fluorescence intensity using MitoTracker ® Green FM.
- RT-qPCR was performed to quantify the mRNA expression level of the DNA methyl transferase 1 (DNMT1), DNA methyl transferase 3a (DNMT3a), DNA methyl transferase 3b (DNMT3b).
- the expression level of the gene was normalized to that of the housekeeping gene GAPDH .
- mRNA level of DNMT1 and DNMT3a could see significantly lower in SCNT CICT group than in the group.
- the mRNA expression level of DNMT3b was lower in the CICT group than in the SCNT group (see FIG. 4).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Plant Pathology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Gene | Primer sequence | Accession number | Product size (bp) |
DNMT1 | F: AGGGAGACGTGGAGATGCTGR: CATGGAGCGCTTGAAGGAG | AY244709 | 194 |
DNMT3a | F: AGACATGTGGGTTGAACCCGR: GGCTCCCACAAGAGATGCAG | AY271298 | 188 |
DNMT3b | F: CAGGATGGGAAGGAGTTTGGAR: CACCAAACCACTGGACCCAC | AY244710 | 151 |
GAPDH | F: CCCAGAATATCATCCCTGCTR: CTGCTTCACCACCTTCTTGA | NM_001034034 | 185 |
Group | No. of cultured zygotes | No. of cloned oocytes | No. (%) of fused embryos* | No. (%) ≥≥ 8/16 cell embryos** | No. (%) of blastocysts*** |
IVF | 258 | - | - | 194 (75.4 ± 1.3)a | 80 (31.2 ± 1.2)a |
SCNT | - | 558 | 381 (68.3 ± 1.5)a | 148 (39.7 ± 2.1)b | 74 (20.2 ± 1.3)b |
CICT | - | 296 | 243 (82.0 ± 0.3)b | 149 (61.5 ± 1.3)c | 70 (28.9 ± 0.8)a |
Group | No. of blastocysts | No. of total cellsper blastocyst | No. of apoptotic cells per blastocyst |
IVF | 15 | 184.0 ± 8.7a | 4.4 ± 0.5a |
SCNT | 15 | 119.3 ± 7.7b | 4.1 ± 0.8a |
CICT | 15 | 176.2 ± 6.5a | 3.5 ± 1.1a |
Claims (7)
- 세포질이 소실된 탈핵된 난모세포에 복제하고자 하는 체세포 및 세포질을 주입하는 단계를 포함하는, 복제배아의 재프로그래밍 효율을 향상시키는 방법.
- 제1항에 있어서,상기 세포질이 소실된 탈핵된 난모세포는 세포질의 20~30 부피%가 소실된 난모세포이며, 상기 세포질을 주입하는 단계는 다른 난모세포에서 20~30 부피%의 세포질을 추출하여 주입하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 체세포 및 세포질을 주입하는 단계는 조작 피펫(manipulation pipette)을 이용하여 상기 탈핵된 난모세포의 난황 주위공간에 체세포 및 세포질을 함께 주입하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 체세포 및 세포질이 주입된 난모세포를 SV 매개 방법을 통해 융합시키는 단계를 추가로 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서,(a) 복제하고자 하는 체세포를 가진 개체로부터 복제하고자 하는 체세포를 추출하는 단계;(b) 체외성숙시킨 난모세포로부터 세포질의 20~30 부피%와 핵이 제거된 탈핵된 난모세포를 준비하는 단계;(c) 공여자 난모세포로부터 20~30 부피%의 세포질을 추출하는 단계;(d) 상기 복제하고자 하는 체세포를 가진 개체로부터 추출된 체세포와 공여자 난모세포로부터 추출한 세포질을 상기 (b) 단계의 탈핵된 난모세포에 주입하는 단계; 및(e) 상기 체세포 및 세포질이 주입된 난모세포를 융합시키는 단계를 포함하는 방법.
- 제1항 내지 제5항 중 어느 한 항의 방법을 이용한 포유동물의 체세포 복제 효율을 증가시키는 방법.
- 제6항에 있어서,(a) 포유동물로부터 복제하고자 하는 체세포를 추출하는 단계;(b) 체외성숙시킨 난모세포로부터 세포질의 20~30 부피%와 핵이 제거된 탈핵된 난모세포를 준비하는 단계;(c) 공여자 난모세포로부터 20~30 부피%의 세포질을 추출하는 단계;(d) 상기 포유동물로부터 추출된 체세포와 공여자 난모세포로부터 추출한 세포질을 상기 (b) 단계의 탈핵된 난모세포에 주입하는 단계;(e) 상기 체세포 및 세포질이 주입된 난모세포를 융합시키는 단계; 및(f) 상기 융합된 난모세포를 배양하는 단계를 포함하는 것을 특징으로 하는 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170126290A KR101985924B1 (ko) | 2017-09-28 | 2017-09-28 | 세포질 이식을 이용한 복제배아의 재프로그래밍 효율 향상 방법 |
KR10-2017-0126290 | 2017-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019066161A1 true WO2019066161A1 (ko) | 2019-04-04 |
Family
ID=65903021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/001691 WO2019066161A1 (ko) | 2017-09-28 | 2018-02-08 | 세포질 이식을 이용한 복제배아의 재프로그래밍 효율 향상 방법 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101985924B1 (ko) |
WO (1) | WO2019066161A1 (ko) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080222745A1 (en) * | 2007-03-07 | 2008-09-11 | Utah State University | Colcemid-Treatment of Oocytes to enhance Nuclear Transfer Cloning |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080018759A (ko) | 2006-08-25 | 2008-02-28 | 엘지이노텍 주식회사 | 윈칩형 rf집적모듈 |
-
2017
- 2017-09-28 KR KR1020170126290A patent/KR101985924B1/ko active IP Right Grant
-
2018
- 2018-02-08 WO PCT/KR2018/001691 patent/WO2019066161A1/ko active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080222745A1 (en) * | 2007-03-07 | 2008-09-11 | Utah State University | Colcemid-Treatment of Oocytes to enhance Nuclear Transfer Cloning |
Non-Patent Citations (5)
Title |
---|
HUA, SONG: "Effects of the removal of cytoplasm on the development of early cloned bovine embryos", ANIMAL REPRODUCTION SCIENCE, vol. 126, 2011, pages 37 - 44, XP028240030, DOI: doi:10.1016/j.anireprosci.2011.05.002 * |
MA, LIBING: "Somatic cell reprogrammed by oocyte: process and barricade", ANIMAL CELLS AND SYSTEMS, vol. 18, no. 3, 4 May 2014 (2014-05-04), pages 161 - 171, XP055586712 * |
SONG, BONG-SEOK: "Inactivated sendai-virus-mediated fusion improves early development of cloned bovine embryos by avoiding endoplasmic-reticulum- stress-associated apoptosis", REPRODUCTION, FERTILITY AND DEVELOPMENT, vol. 23, 2011, pages 826 - 836 * |
WEN , DUANCHENG: "Histone variant H3.3 is an essential maternal factor for oocyte reprogramming", PNAS, vol. 111, no. 20, 20 May 2014 (2014-05-20), pages 7325 - 7330, XP055240348, DOI: doi:10.1073/pnas.1406389111 * |
XU, LIANGUANG, IMPROVEMENT OF REPROGRAMMING EFFICIENCY OF BOVINE CLONED EMBRYOS BY CYTOPLASM RESTORATION OF ENUCLEATED OOCYTE, August 2017 (2017-08-01), pages 1 - 37 * |
Also Published As
Publication number | Publication date |
---|---|
KR101985924B1 (ko) | 2019-06-04 |
KR20190036865A (ko) | 2019-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Edwards et al. | Oocyte polarity and cell determination in early mammalian embryos. | |
US8551705B2 (en) | Use of haploid genomes for genetic diagnosis, modification and multiplication | |
Eakin et al. | Tetraploid development in the mouse | |
Cervera et al. | Trichostatin A affects histone acetylation and gene expression in porcine somatic cell nucleus transfer embryos | |
Liu et al. | Cross-species single-cell transcriptomic analysis reveals pre-gastrulation developmental differences among pigs, monkeys, and humans | |
US20090133137A1 (en) | Method of cloning animals | |
US6194635B1 (en) | Embryonic germ cells, method for making same, and using the cells to produce a chimeric porcine | |
US20050273870A1 (en) | Preparation and selection of donor cells for nuclear transplantation | |
Galli et al. | Introduction to cloning by nuclear transplantation | |
US6545199B1 (en) | Embryonic germ cells, method for making same, and using the cells to produce a chimeric porcine | |
KR20200145804A (ko) | 멜라토닌을 포함하는, 배아 발달용 조성물 및 이를 이용하여 배아 발달의 효율을 향상시키는 방법 | |
Yatsenko et al. | The power of mouse genetics to study spermatogenesis | |
EP0774510A1 (en) | Ungulate eg cell | |
WO2006041910A2 (en) | Stem cells derived from uniparental embryos and methods of use thereof | |
KR102204413B1 (ko) | Rad51 활성화제를 포함하는, 배아 발달용 조성물 및 이를 이용하여 배아 발달률을 향상시키는 방법 | |
Yang et al. | Improving in vitro development of cloned bovine embryos with hybrid (Holstein–Chinese Yellow) recipient oocytes recovered by ovum pick up | |
Hao et al. | Developmental competence of porcine parthenogenetic embryos relative to embryonic chromosomal abnormalities | |
WO2019066161A1 (ko) | 세포질 이식을 이용한 복제배아의 재프로그래밍 효율 향상 방법 | |
Sha et al. | Fates of donor and recipient mitochondrial DNA during generation of interspecies SCNT-derived human ES-like cells | |
US20220025323A1 (en) | Methods for generating, evaluating, gene editing and cloning pluripotent stem cells comprising a lethal haplotype | |
Kerkis et al. | Actual achievements on germ cells and gametes derived from pluripotent stem cells | |
Saadeldin et al. | Blastocysts derivation from somatic cell fusion with premature oocytes (prematuration somatic cell fusion) | |
Ernst et al. | Development of an efficient method to produce uniformly haploid parthenogenones | |
WO2002019811A2 (en) | Generation of transgenic animals using nuclear transfer and oocytes at the germinal vesicle stage | |
Randall | Optimized vitrification, cell cycle compatibility and volume of cytoplasts for bovine embryonic cloning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18860364 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18860364 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 02/02/2021) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18860364 Country of ref document: EP Kind code of ref document: A1 |